Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?
Executive Summary
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
You may also be interested in...
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
Fitusiran's mechanism of reducing antithrombin levels could apply to all hemophilia patients, as well as those with other rare bleeding disorders. Reducing antithrombin increases thrombin levels and helps to increase normal clotting.
Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Bayer Highlights Hemophilia Strategy As Newer Drugs Carry Pharma Unit In Q2
Company will prioritize potential Kogenate successor Kovaltry for hemophilia A, and delay filing of BAY 94-9027.